Eris Lifesciences' Q2 net rises 16%, consolidated income grows 14.5%

Eris continued to demonstrate strong focus on its top 15 power brands

Eris Lifesciences Ltd reported a growth of 16.16 per cent in its consolidated profit after tax (PAT) for the quarter ended September 30, 2020. The drug maker saw its consolidated net profit for Q2FY21 rise to Rs 107.7 crore as compared to Rs 92.71 crore in the same quarter last year.]
 

The company's consolidated total income, on the other hand, grew 14.52 per cent to Rs 332.07 crore as compared to Rs 289.96 crore in corresponding period of the last year.
 

The company informed the exchanges that during the second quarter its continued to focus on super-specialty and execution led